Pyxis Oncology, Inc. announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.095 USD | -6.50% | -1.72% | +74.17% |
10/06 | Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors | CI |
14/05 | Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.17% | 195M | |
+15.89% | 121B | |
+19.74% | 113B | |
+17.47% | 26.02B | |
-24.99% | 19.39B | |
-19.51% | 15.91B | |
-18.40% | 15.09B | |
-46.87% | 15.06B | |
+62.76% | 14.93B | |
+5.49% | 13.85B |
- Stock Market
- Equities
- PYXS Stock
- News Pyxis Oncology, Inc.
- Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs